Enhancement of IL-10 bioactivity using an IL-10 peptide-based vaccine exacerbates Leishmania major infection and improves airway inflammation in mice

Vaccine

Volumn 28, Issue 7, 2010, Pages 1838-1846

  Zhou, Gang ^a   Ma, Yanbing ^a   Jia, Ping ^a   Guan, Qingdong ^a   Uzonna, Jude E ^a   Peng, Zhikang ^a  

^a UNIVERSITY OF MANITOBA   (Canada)

Author keywords

Asthma; IL 10 vaccine; Leishmania major

Indexed keywords

AUTOANTIBODY; GAMMA INTERFERON; HEPATITIS B CORE ANTIGEN; IMMUNOGLOBULIN E ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; INTERLEUKIN 10; INTERLEUKIN 10 ANTIBODY; INTERLEUKIN 4; LEISHMANIA VACCINE; OVALBUMIN; PEPTIDE VACCINE; POLYCLONAL ANTIBODY; RECOMBINANT INTERLEUKIN 10; UNCLASSIFIED DRUG; VIRUS LIKE PARTICLE VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY TITER; ANTIINFLAMMATORY ACTIVITY; ARTICLE; ASTHMA; CELL HYPERPLASIA; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE EXACERBATION; DOSE RESPONSE; EOSINOPHIL; FEMALE; GOBLET CELL; IMMUNOLOGICAL TOLERANCE; INFLAMMATORY CELL; LEISHMANIA MAJOR; LYMPH NODE CELL; MOUSE; NONHUMAN; PNEUMONIA; PRIORITY JOURNAL; RECOMBINANT DNA TECHNOLOGY; SKIN LEISHMANIASIS; VIRUS LIKE AGENT;

ANIMALS; ASTHMA; AUTOANTIBODIES; DISEASE PROGRESSION; EOSINOPHILS; FEMALE; HEPATITIS B CORE ANTIGENS; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G; INTERFERON-GAMMA; INTERLEUKIN-10; INTERLEUKIN-4; LEISHMANIA MAJOR; LEISHMANIASIS, CUTANEOUS; MICE; MICE, INBRED BALB C; PNEUMONIA; RECOMBINANT PROTEINS; VACCINES, SUBUNIT;

EID: 75249101300     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.11.081     Document Type: Article

References (68)

1. Jankovic D., and Trinchieri G. IL-10 or not IL-10: that is the question. Nat Immunol 8 December (12) (2007) 1281-1283
2. Stumhofer J.S., Silver J.S., Laurence A., Porrett P.M., Harris T.H., Turka L.A., et al. Interleukins 27 and 6 induce STAT3-mediated T cell production of interleukin 10. Nat Immunol 8 December (12) (2007) 1363-1371
3. O'Garra A., Barrat F.J., Castro A.G., Vicari A., and Hawrylowicz C. Strategies for use of IL-10 or its antagonists in human disease. Immunol Rev 223 June (2008) 114-131
4. Trinchieri G. Interleukin-10 production by effector T cells: Th1 cells show self control. J Exp Med 204 February (2) (2007) 239-243
5. Movahedi M., Mahdaviani S.A., Rezaei N., Moradi B., Dorkhosh S., and Amirzargar A.A. IL-10, TGF-beta, IL-2, IL-12, and IFN-gamma cytokine gene polymorphisms in asthma. J Asthma 45 November (9) (2008) 790-794
6. Speiran K., Bailey D.P., Fernando J., Macey M., Barnstein B., Kolawole M., et al. Endogenous suppression of mast cell development and survival by IL-4 and IL-10. J Leukoc Biol 85 February (5) (2009) 826-836
7. Kennedy Norton S., Barnstein B., Brenzovich J., Bailey D.P., Kashyap M., Speiran K., et al. IL-10 suppresses mast cell IgE receptor expression and signaling in vitro and in vivo. J Immunol 180 March (5) (2008) 2848-2854
8. Kane M.M., and Mosser D.M. The role of IL-10 in promoting disease progression in leishmaniasis. J Immunol 166 January (2) (2001) 1141-1147
9. Klenerman P., and Ludewig B. Virus scores a perfect 10. Nat Med 12 November (11) (2006) 1246-1248
10. Okwor I., and Uzonna J. Persistent parasites and immunologic memory in cutaneous leishmaniasis: implications for vaccine designs and vaccination strategies. Immunol Res 41 2 (2008) 123-136
11. O'Garra A., and Vieira P. T(H)1 cells control themselves by producing interleukin-10. Nat Rev Immunol 7 June (6) (2007) 425-428
12. Groux H., Cottrez F., Rouleau M., Mauze S., Antonenko S., Hurst S., et al. A transgenic model to analyze the immunoregulatory role of IL-10 secreted by antigen-presenting cells. J Immunol 162 February (3) (1999) 1723-1729
13. Belkaid Y., Piccirillo C.A., Mendez S., Shevach E.M., and Sacks D.L. CD4+CD25+ regulatory T cells control Leishmania major persistence and immunity. Nature 420 December (6915) (2002) 502-507
14. Anderson C.F., Oukka M., Kuchroo V.J., and Sacks D. CD4(+)CD25(-)Foxp3(-) Th1 cells are the source of IL-10-mediated immune suppression in chronic cutaneous leishmaniasis. J Exp Med 204 February (2) (2007) 285-297
15. Brooks D.G., Trifilo M.J., Edelmann K.H., Teyton L., McGavern D.B., and Oldstone M.B. Interleukin-10 determines viral clearance or persistence in vivo. Nat Med 12 November (11) (2006) 1301-1309
16. Ejrnaes M., Filippi C.M., Martinic M.M., Ling E.M., Togher L.M., Crotty S., et al. Resolution of a chronic viral infection after interleukin-10 receptor blockade. J Exp Med 203 October (11) (2006) 2461-2472
17. Kobayashi F., Ishida H., Matsui T., and Tsuji M. Effects of in vivo administration of anti-IL-10 or anti-IFN-gamma monoclonal antibody on the host defense mechanism against Plasmodium yoelii yoelii infection. J Vet Med Sci 62 June (6) (2000) 583-587
18. Arai T., Hiromatsu K., Nishimura H., Kimura Y., Kobayashi N., Ishida H., et al. Effects of in vivo administration of anti-IL-10 monoclonal antibody on the host defence mechanism against murine Salmonella infection. Immunology 85 July (3) (1995) 381-388
19. Ravirajan C.T., Wang Y., Matis L.A., Papadaki L., Griffiths M.H., Latchman D.S., et al. Effect of neutralizing antibodies to IL-10 and C5 on the renal damage caused by a pathogenic human anti-dsDNA antibody. Rheumatology (Oxford) 43 April (4) (2004) 442-447
20. Ma Y., Hayglass K.T., Becker A.B., Fan Y., Yang X., Basu S., et al. Novel recombinant interleukin-13 peptide-based vaccine reduces airway allergic inflammatory responses in mice. Am J Respir Crit Care Med 176 (2007) 439-445
21. Xu G., Liu D., Fan Y., Yang X., Korner H., Fu Y.X., et al. Lymphotoxin alpha beta 2 (membrane lymphotoxin) is critically important for resistance to Leishmania major infection in mice. J Immunol 179 October (8) (2007) 5358-5366
22. Perosa F., Carbone R., Ferrone S., and Dammacco F. Purification of human immunoglobulins by sequential precipitation with caprylic acid and ammonium sulphate. J Immunol Methods 128 March (1) (1990) 9-16
23. Hillyer L.M., and Woodward B. Interleukin-10 concentration determined by sandwich enzyme-linked immunosorbent assay is unrepresentative of bioactivity in murine blood. Am J Physiol Regul Integr Comp Physiol 285 December (6) (2003) R1514-R1519
24. Hillyer L., Dao B., Niemiec P., Lee S., Doidge M., Bemben I., et al. Elevated bioactivity of the tolerogenic cytokines, interleukin-10 and transforming growth factor-beta, in the blood of acutely malnourished weanling mice. Exp Biol Med (Maywood) 231 September (8) (2006) 1439-1447
25. Ma Y., HayGlass K.T., Becker A.B., Halayko A.J., Basu S., Simons F.E.R., et al. Novel cytokine peptide-based vaccines: an interleukin-4 vaccine suppresses airway allergic responses in mice. Allergy 62 (2007) 675-682
26. Akdis C.A., and Akdis M. Mechanisms and treatment of allergic disease in the big picture of regulatory T cells. J Allergy Clin Immunol 123 April (4) (2009) 735-746 [quiz 47-8]
27. Ogawa Y., Duru E.A., and Ameredes B.T. Role of IL-10 in the resolution of airway inflammation. Curr Mol Med 8 August (5) (2008) 437-445
28. Zuany-Amorim C., Manlius C., Dalum I., Jensen M.R., Gautam A., Pay G., et al. Induction of TNF-alpha autoantibody production by AutoVac TNF106: a novel therapeutic approach for the treatment of allergic diseases. Int Arch Allergy Immunol 133 February (2) (2004) 154-163
29. Richard M., Grencis R.K., Humphreys N.E., Renauld J.C., and Van Snick J. Anti-IL-9 vaccination prevents worm expulsion and blood eosinophilia in Trichuris muris-infected mice. Proc Natl Acad Sci USA 97 2 (2000) 767-772
30. Rad F.H., Le Buanec H., Paturance S., Larcier P., Genne P., Ryffel B., et al. VEGF kinoid vaccine, a therapeutic approach against tumor angiogenesis and metastases. Proc Natl Acad Sci USA 104 February (8) (2007) 2837-2842
31. Capini C.J., Bertin-Maghit S.M., Bessis N., Haumont P.M., Bernier E.M., Muel E.G., et al. Active immunization against murine TNFalpha peptides in mice: generation of endogenous antibodies cross-reacting with the native cytokine and in vivo protection. Vaccine 22 August (23-24) (2004) 3144-3153
32. Wang C.Y., Walfield A.M., Fang X., Hammerberg B., Ye J., Li M.L., et al. Synthetic IgE peptide vaccine for immunotherapy of allergy. Vaccine 21 April (15) (2003) 1580-1590
33. Jegerlehner A., Tissot A., Lechner F., Sebbel P., Erdmann I., Kundig T., et al. A molecular assembly system that renders antigens of choice highly repetitive for induction of protective B cell responses. Vaccine 20 August (25-26) (2002) 3104-3112
34. Spohn G., Guler R., Johansen P., Keller I., Jacobs M., Beck M., et al. A virus-like particle-based vaccine selectively targeting soluble TNF-alpha protects from arthritis without inducing reactivation of latent tuberculosis. J Immunol 178 June (11) (2007) 7450-7457
35. Ma Y., Ma A.G., and Peng Z. A potential immunotherapy approach: mucosal immunization with an IL-13 peptide-based and virus-like particle vaccine in a mouse asthma model. Vaccine 25 (2007) 8091-8099
36. Nardin E.H., Oliveira G.A., Calvo-Calle J.M., Wetzel K., Maier C., Birkett A.J., et al. Phase I testing of a malaria vaccine composed of hepatitis B virus core particles expressing Plasmodium falciparum circumsporozoite epitopes. Infect Immun 72 November (11) (2004) 6519-6527
37. Milich D.R., Chen M., Schodel F., Peterson D.L., Jones J.E., and Hughes J.L. Role of B cells in antigen presentation of the hepatitis B core. Proc Natl Acad Sci USA 94 December (26) (1997) 14648-14653
38. Chackerian B., Lenz P., Lowy D.R., and Schiller J.T. Determinants of autoantibody induction by conjugated papillomavirus virus-like particles. J Immunol 169 December (11) (2002) 6120-6126
39. Scharton-Kersten T., Afonso L.C., Wysocka M., Trinchieri G., and Scott P. IL-12 is required for natural killer cell activation and subsequent T helper 1 cell development in experimental leishmaniasis. J Immunol 154 May (10) (1995) 5320-5330
40. Scott P., Pearce E., Cheever A.W., Coffman R.L., and Sher A. Role of cytokines and CD4+ T-cell subsets in the regulation of parasite immunity and disease. Immunol Rev 112 December (1989) 161-182
41. Scott P. The role of TH1 and TH2 cells in experimental cutaneous leishmaniasis. Exp Parasitol 68 April (3) (1989) 369-372
42. Sacks D.L., Scott P.A., Asofsky R., and Sher F.A. Cutaneous leishmaniasis in anti-IgM-treated mice: enhanced resistance due to functional depletion of a B cell-dependent T cell involved in the suppressor pathway. J Immunol 132 April (4) (1984) 2072-2077
43. Hoerauf A., Solbach W., Lohoff M., and Rollinghoff M. The Xid defect determines an improved clinical course of murine leishmaniasis in susceptible mice. Int Immunol 6 August (8) (1994) 1117-1124
44. Buxbaum L.U., and Scott P. Interleukin 10- and Fcgamma receptor-deficient mice resolve Leishmania mexicana lesions. Infect Immun 73 April (4) (2005) 2101-2108
45. Miles S.A., Conrad S.M., Alves R.G., Jeronimo S.M., and Mosser D.M. A role for IgG immune complexes during infection with the intracellular pathogen Leishmania. J Exp Med 201 March (5) (2005) 747-754
46. Woelbing F., Kostka S.L., Moelle K., Belkaid Y., Sunderkoetter C., Verbeek S., et al. Uptake of Leishmania major by dendritic cells is mediated by Fcgamma receptors and facilitates acquisition of protective immunity. J Exp Med 203 January (1) (2006) 177-188
47. Couper K.N., Blount D.G., and Riley E.M. IL-10: the master regulator of immunity to infection. J Immunol 180 May (9) (2008) 5771-5777
48. Henry E., Desmet C.J., Garze V., Fievez L., Bedoret D., Heirman C., et al. Dendritic cells genetically engineered to express IL-10 induce long-lasting antigen-specific tolerance in experimental asthma. J Immunol 181 November (10) (2008) 7230-7242
49. Correa I., Veny M., Esteller M., Pique J.M., Yague J., Panes J., et al. Defective IL-10 production in severe phenotypes of Crohn's disease. J Leukoc Biol February (5) (2009) 896-903
50. Londono D., Marques A., Hornung R.L., and Cadavid D. IL-10 helps control pathogen load during high-level bacteremia. J Immunol 181 August (3) (2008) 2076-2083
51. Sun J., Madan R., Karp C.L., and Braciale T.J. Effector T cells control lung inflammation during acute influenza virus infection by producing IL-10. Nat Med 15 February (3) (2009) 277-284
52. Krishnamurthy P., Rajasingh J., Lambers E., Qin G., Losordo D.W., and Kishore R. IL-10 inhibits inflammation and attenuates left ventricular remodeling after myocardial infarction via activation of STAT3 and suppression of HuR. Circ Res 104 January (2) (2009) e9-18
53. Hoegl S., Boost K.A., Czerwonka H., Dolfen A., Scheiermann P., Muhl H., et al. Inhaled IL-10 reduces biotrauma and mortality in a model of ventilator-induced lung injury. Respir Med 103 March (3) (2009) 463-470
54. Frossard C.P., and Eigenmann P.A. The role of IL-10 in preventing food-induced anaphylaxis. Expert Opin Biol Ther 8 September (9) (2008) 1309-1317
55. Nemazee D.A., and Sato V.L. Enhancing antibody: a novel component of the immune response. Proc Natl Acad Sci USA 79 June (12) (1982) 3828-3832
56. Hill R.A., and Pell J.M. Regulation of insulin-like growth factor I (IGF-I) bioactivity in vivo: further characterization of an IGF-I-enhancing antibody. Endocrinology 139 March (3) (1998) 1278-1287
57. Hill R.A., Flick-Smith H.C., Dye S., and Pell J.M. Actions of an IGF-I-enhancing antibody on IGF-I pharmacokinetics and tissue distribution: increased IGF-I bioavailability. J Endocrinol 152 January (1) (1997) 123-130
58. Beattie J., Bramani S., Secchi C., and Mockridge J. Binding and signalling properties of a growth hormone enhancing monoclonal antibody. Mol Cell Biochem 198 August (1-2) (1999) 61-67
59. Beattie J., and Holder A.T. Location of an epitope defined by an enhancing monoclonal antibody to growth hormone: some structural details and biological implications. Mol Endocrinol 8 August (8) (1994) 1103-1110
60. He X., Sun X., Wang J., Wang X., Zhang Q., Tzipori S., et al. Antibody-enhanced Fc gamma receptor-mediated endocytosis of Clostridium difficile toxin A. Infect Immun 77 June (6) (2009) 2294-2303
61. Shieh H.M., Bass R.T., Wang B.S., Corbett M.J., and Buckwalter B.L. Epitope mapping and analysis of a growth-enhancing monoclonal antibody by limited tryptic digestion of porcine GH. J Endocrinol 145 April (1) (1995) 169-174
62. Lee C.N., Robinson J., Cheng Y.L., Essex M., and Lee T.H. Influence of deletions in N or C terminus of HIV-1 glycoprotein 120 on binding of infectivity-enhancing antibody. AIDS Res Hum Retroviruses 10 September (9) (1994) 1065-1069
63. Kliks S.C., Shioda T., Haigwood N.L., and Levy J.A. V3 variability can influence the ability of an antibody to neutralize or enhance infection by diverse strains of human immunodeficiency virus type 1. Proc Natl Acad Sci USA 90 December (24) (1993) 11518-11522
64. Robinson Jr. W.E. Enhancing antibody and its role in acquired immunodeficiency syndrome. West J Med 158 March (3) (1993) 297-298
65. Jones B.C., Logsdon N.J., Josephson K., Cook J., Barry P.A., and Walter M.R. Crystal structure of human cytomegalovirus IL-10 bound to soluble human IL-10R1. Proc Natl Acad Sci USA 99 July (14) (2002) 9404-9409
66. Zdanov A., Schalk-Hihi C., and Wlodawer A. Crystal structure of human interleukin-10 at 1.6 A resolution and a model of a complex with its soluble receptor. Protein Sci 5 October (10) (1996) 1955-1962
67. Gesser B., Leffers H., Jinquan T., Vestergaard C., Kirstein N., Sindet-Pedersen S., et al. Identification of functional domains on human interleukin 10. Proc Natl Acad Sci USA 94 December (26) (1997) 14620-14625
68. Kim J.M., Brannan C.I., Copeland N.G., Jenkins N.A., Khan T.A., and Moore K.W. Structure of the mouse IL-10 gene and chromosomal localization of the mouse and human genes. J Immunol 148 June (11) (1992) 3618-3623